Skip to content

Thrombin in Cardiac Surgery

Diagnosis and Management of Impaired Thrombin Generation in Cardiac Surgery

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04762576
Enrollment
200
Registered
2021-02-21
Start date
2022-08-10
Completion date
2023-01-01
Last updated
2022-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Surgical Procedures, Coagulation Disorder, Hemostatic Disorder, Surgical Blood Loss, Thrombin

Brief summary

Coagulopathy, bleeding, and transfusion are common in cardiac surgical patients. Our collaborator has developed a novel point of care device that can be used to assess thrombin generation in real-time in cardiac surgical patients. The investigators will measure thrombin generation using our novel device and compare it to standard methods, while examining the association of thrombin parameters with bleeding and other clinical outcomes.

Detailed description

This is a prospective observational cohort study of 200 cardiac surgical patients. Thrombin generation via our novel point of care thrombin generation assay as well as calibrated automated thrombography (CAT) will be measured at three time points: (1) before surgery; (2) post-CPB after heparin reversal with protamine; (3) at the time of chest closure or 60 minutes after heparin reversal with protamine. Clinicians will remain blinded to the measures. Recruitment will continue until the investigators enroll 50 patients with significant impaired thrombin generation capacity (\>50% drop from baseline) and 50 patients who receive hemostatic therapies. Patients will be followed for 7 days postoperatively to assess individual products transfused.

Interventions

None listed

Sponsors

McMaster University
CollaboratorOTHER
University Health Network, Toronto
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

-All adult patients (\> 18 years of age) undergoing cardiac surgery at Toronto General Hospital will be offered participation.

Exclusion criteria

-Patients who are unable to consent to the study or who refuse participation will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Thrombin Generation, as assessed by the Time to PeakThe change in thrombin generation will be assessed from preoperative baseline up until 12 hours post-operativelyThe co-primary thrombin generation parameter of interest is the Time to Peak, expressed in seconds. The change in thrombin generation in patients undergoing cardiac surgery before and after cardiopulmonary bypass using our new point-of-care thrombin sensor and the established laboratory-based calibrated automated thrombogram (CAT) assay will be assessed.
Thrombin Generation, as assessed by the Peak HeightThe change in thrombin generation will be assessed from preoperative baseline up until 12 hours post-operativelyThe co-primary thrombin generation parameter of interest is the Peak Height, expressed in nM. The change in thrombin generation in patients undergoing cardiac surgery before and after cardiopulmonary bypass using our new point-of-care thrombin sensor and the established laboratory-based calibrated automated thrombogram (CAT) assay will be assessed.
Thrombin Generation, as assessed by the Endogenous Thrombin Potential (ETP)The change in thrombin generation will be assessed from preoperative baseline up until 12 hours post-operativelyThe primary thrombin generation parameter of interest is the endogenous thrombin potential, or ETP, expressed in nM\*min. The change in thrombin generation in patients undergoing cardiac surgery before and after cardiopulmonary bypass using our new point-of-care thrombin sensor and the established laboratory-based calibrated automated thrombogram (CAT) assay will be assessed.
Thrombin Generation, as assessed by the Lag TimeThe change in thrombin generation will be assessed from preoperative baseline up until 12 hours post-operativelyThe co-primary thrombin generation parameter of interest is the Lag Time, expressed in seconds. The change in thrombin generation in patients undergoing cardiac surgery before and after cardiopulmonary bypass using our new point-of-care thrombin sensor and the established laboratory-based calibrated automated thrombogram (CAT) assay will be assessed.

Secondary

MeasureTime frameDescription
Total amount of Fibrinogen Concentrate transfusedFrom intra-operatively up to 12 hours post-operativelyThe total number of grams of fibrinogen concentrate transfused will be recorded
Total amount of Prothrombin Complex Concentrates transfusedFrom intra-operatively up to 12 hours post-operativelyThe total number of prothrombin complex concentrate units will be recorded
Total Units of Red Blood Cells TransfusedFrom intra-operatively up to 12 hours post-operativelyThe total number of red blood cells units transfused will be recorded
Total Units of Platelets TransfusedFrom intra-operatively up to 12 hours post-operativelyThe total number of platelets units transfused will be recorded
Total Units of Frozen Plasma TransfusedFrom intra-operatively up to 12 hours post-operativelyThe total number of frozen plasma units transfused will be recorded

Other

MeasureTime frameDescription
Chest tube drainageFrom intra-operatively to within 12 hours post-operativelyBlood loss from chest tube drainage will be assessed in mL
Return to the Operating Room for Bleeding or Delayed Chest ClosureFrom intra-operatively to within 12 hours post-operativelyInstances of return to the operating room for re-exploration or a delay in chest closure will be assessed

Countries

Canada

Contacts

Primary ContactJustyna Bartoszko, MD MSc FRCPC
justyna.bartoszko@uhn.ca416-340-4800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026